PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Nicotinic acid - Familial hypercholesterolaemia
PAD Profile : Nicotinic acid - Familial hypercholesterolaemia
Keywords :
high cholesterol, raised cholesterol, lipid lowering, lipid modification, hyperlipidaemia, FH
Brand Names Include :
Niacin, Niaspan
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
01 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Nicotinic acid is no longer available as a licensed product in the UK (Niaspan license withdrawn in June 2011), and other licensed treatments are available for FH. Therefore, the PCN recommends nicotinic acid is classified as BLACK on the traffic light system for this indication.
Patients that are currently being treated with Nicotinic Acid for the treatment of familial hypercholesterolaemia* should have their treatment reviewed. It should be a shared decision between the NHS clinician and the patient as to whether it is appropriate for the treatment to be stopped.
*Some patient’s may have been initiated on Nicotinic Acid prior to NICE recommendations
NOTE - NICE CG71 (updated in July 2016) recommends patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration of treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
At the time of publication of CG71 nicotinic acid was available as a licensed product.
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs